When was Perthera founded?

Perthera was founded in 2012 and raised its 1st funding round 3 years after it was founded.

Where is Perthera located?

Perthera is headquartered in Mclean, United States. It is registered at Holliston, Massachusetts.

How many employees does Perthera have?

As of Jul 31, 2026, the latest employee count at Perthera is 17.

Is Perthera a funded company?

Perthera is a funded company, having raised a total of $17.8M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 11, 2015.

When was the latest funding round of Perthera?

Perthera's latest funding was a $***** Series A round on Sep 30, 2022, with participation from 0 investor. Its primary sector is Healthcare IT. In United States, the Healthcare IT sector has seen $5.68B in funding in 2026 to date.

Where does Perthera rank among its competitors?

Perthera ranks 72nd amongst 528 active competitors, of which 161 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Tempus, which secured $460M in Jul, 2026.

Who are the top competitors of Perthera?

Perthera's top competitors include Tempus, MedGenome and Artera. Among them, Tempus secured the most recent funding round in July, 2026.

Perthera - 2026 Company Profile, Team, Funding & Competitors

Perthera is a series A company based in Mclean (United States), founded in 2012 by Dendy Young. It operates as a Personalized molecular cancer profiling through genomics and proteomics. Perthera has raised $17.8M in funding from Pilot Growth Equity. The company has 528 active competitors, including 161 funded and 92 that have exited. Its top competitors include companies like Tempus, MedGenome and Artera.

Company Details

Personalized molecular cancer profiling through genomics and proteomics. Through the company’s PrecisOn process, Perthera will provide oncologists with a comprehensive understanding of the molecular architecture of their patients’ tumors. The multiple molecular analyses of each tumor will be integrated into Perthera’s Expert Oncologist system (also known as ExpO), an expert learning database that sources the most current clinical knowledge and research/drug information available, to facilitate analysis of multi-omic molecular profiles in context with the patient’s medical history.

Website: www.perthera.com
Social
Registered Address: Holliston, Massachusetts

Key Metrics

Founded Year

2012

Location

Mclean, United States

Stage

Series A

Total Funding

$17.8M in 6 rounds

Latest Funding Round

Series A, Sep 30, 2022, $*****

Investors

Pilot Growth Equity & 1 more

Ranked

72^nd among 528 active competitors

Employee Count

17 as on Jul 31, 2026

Similar Companies

Tempus & 717 more

View Perthera's full profile

Perthera is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PERTHERA INC. CIN: 452740870 , United States, Active		-	9 (As on Dec 31, 2024)	-

Perthera has raised a total funding of $17.8M over 6 rounds. Its first funding round was on Aug 11, 2015. Perthera has 2 institutional investors.

Here is the list of recent funding rounds of Perthera:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 30, 2022	6908208	Series A	5105152	1136470	3039484	1503228
Jan 07, 2019	9810877	Series A	5667758	2567332	1873982	6724313
Dec 26, 2017	5269440	Series A	1622345	8607737	6129707	3132008

Access funding benchmarks and valuations. Sign up today!

View details of Perthera's funding rounds and investors

The founders of Perthera is Dendy Young.

Here are the details of Perthera's key team members:

Dendy Young: Co-Founder & Chairman of Perthera and founder of 1 other company. They serve on the board of 1 company.

View details of Perthera's Founder profiles and Board Members

Perthera's employee count trend

Perthera has 17 employees as of Jul 26. Here is Perthera's employee count trend over the years:

Uncover Perthera's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Perthera include Tempus, MedGenome and Artera. Here is the list of Top 10 competitors of Perthera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tempus 2015, Chicago (United States), Public	Developer of genomic testing and artificial intelligence tools for medicine	$1.05B	T. Rowe Price, New Enterprise Associates ... & 11 others	77/100
2nd	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	70/100
3rd	Artera 2021, Menlo Park (United States), Series A	AI-derived prognostic biomarker test for cancer detection	$135M	Walden Catalyst, EDBI & 23 others	68/100
4th	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
5th	4baseCare 2018, Bengaluru (India), Series B	Provider of precision oncology solutions, including genomic testing and digital health	$25.9M	Tremis Consultancy, Yali Capital & 41 others	67/100
6th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	66/100
7th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Novartis & 10 others	66/100
8th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
9th	CancerIQ 2013, Chicago (United States), Series B	Cloud-based platform to doctors, for identifying cancer risk patients and delivering care plans	$24.8M	Amgen, Decathlon Capital Partners & 11 others	62/100
10th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
72nd	Perthera 2012, Mclean (United States), Series A	Personalized molecular cancer profiling through genomics and proteomics	$17.8M	Invictus Growth, Pilot Growth Equity	47/100